⌕
Altimmune · ALT · Nasdaq
Tenet 54 · Mixed
Compare
$1.56−5.17%At closeTenet 54 · Mixed
$1.56−0.09 (−5.17%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Altimmune (ALT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ALT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Zacks Investment ResearchNov 13, 2026 · 08:25 ET
ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns

Altimmune's Q3 loss is wider than estimates as rising R&D costs weigh on earnings, while pemvidutide advances across MASH, AUD and ALD programs.…

ALT −5.2% todayRead at source ↗
● Seeking AlphaNov 12, 2026 · 17:18 ET
Altimmune: Still Too Late And Too Capital-Intensive

Altimmune remains a 'Sell' as pemvidutide lacks clear differentiation in the competitive MASH landscape and faces significant funding challenges. ALT's share count has doubled year-over-year, with further dilution likely…

ALT −5.2% todayRead at source ↗
● Seeking AlphaNov 12, 2026 · 13:09 ET
Altimmune, Inc. (ALT) Q3 2026 Earnings Call Transcript

Altimmune, Inc. (ALT) Q3 2026 Earnings Call Transcript…

ALT −5.2% todayRead at source ↗
● MarketBeatNov 12, 2026 · 11:16 ET
What Altimmune (ALT) Said on Its Q3 Earnings Call

Altimmune NASDAQ: ALT is ramping up a late-stage trial of its experimental drug pemvidutide for a serious liver disease and preparing for a December meeting with the U.S. Food and Drug Administration on a potential phase…

ALT −5.2% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Altimmune Announces Third Quarter 2026 Financial Results and Business Update

Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-Phase 2 meeting with FDA for AUD …

ALT −5.2% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 07:15 ETCOMPANY'S OWN WORDS
Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology

Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile…

ALT −5.2% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 12:30 ETCOMPANY'S OWN WORDS
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder

Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable tolera…

ALT −5.2% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 10:00 ETCOMPANY'S OWN WORDS
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026

First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)…

ALT −5.2% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver dise…

ALT −5.2% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution

Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill, …

ALT −5.2% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral presentation to feature n…

ALT −5.2% todayRead at source ↗
● MarketBeatOct 1, 2026 · 07:02 ET
Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, …

ALT −5.2% todayRead at source ↗
● GlobeNewsWireSep 23, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Altimmune to Participate in Stifel Cardiometabolic Forum

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that manageme…

ALT −5.2% todayRead at source ↗
● Defense WorldSep 16, 2026 · 01:29 ET
Critical Survey: Denali Therapeutics (NASDAQ:DNLI) vs. Altimmune (NASDAQ:ALT)

Altimmune (NASDAQ: ALT - Get Free Report) and Denali Therapeutics (NASDAQ: DNLI - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strengt…

ALT −5.2% todayRead at source ↗
● Zacks Investment ResearchSep 11, 2026 · 12:31 ET
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?…

ALT −5.2% todayRead at source ↗
● GlobeNewsWireSep 9, 2026 · 08:30 ET
Alpha Liquid Terminal Relaunches as the ALT/X Compute Terminal, Pivoting to GPU Pricing, Power and AI Infrastructure Market Data

New York, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Alpha AI Corporation ("Alpha AI"), developer of the Alpha Liquid Terminal ("ALTx"), today announced the relaunch of its platform as the ALT/X Compute Terminal , refocusing…

ALT −5.2% todayRead at source ↗

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just ALT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.